A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours

BACKGROUND: We conducted a phase I trial evaluating pembrolizumab+hypofractionated radiotherapy (HFRT) for patients with metastatic cancers. METHODS: There were two strata (12 patients each): (i) NSCLC/melanoma progressing on prior anti-PD-1 therapy, (ii) other cancer types; anti-PD-1-naive. Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Maity, Amit, Mick, Rosemarie, Huang, Alexander C., George, Sangeeth M., Farwell, Michael D., Lukens, John N., Berman, Abigail T., Mitchell, Tara C., Bauml, Josh, Schuchter, Lynn M., O’Hara, Mark, Lin, Lilie L., Demichele, Angela, Christodouleas, John P., Haas, Naomi B., Patsch, Dana M., Hahn, Stephen M., Minn, Andy J., Wherry, E. John, Vonderheide, Robert H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251028/
https://www.ncbi.nlm.nih.gov/pubmed/30318516
http://dx.doi.org/10.1038/s41416-018-0281-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251028/
https://www.ncbi.nlm.nih.gov/pubmed/30318516
http://dx.doi.org/10.1038/s41416-018-0281-9

Ejemplares similares